TrialDiabetes, obesity & metabolism2015

Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial.

J Rosenstock et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.